Telix and Regeneron Partner to Advance Radiopharmaceutical Therapies
Telix Pharmaceuticals and Regeneron Pharmaceuticals have entered a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership merges Telix's radiopharmaceutical expertise with Regeneron's proficiency in antibody discovery and oncology.
The collaboration focuses on leveraging Telix's development platform and global manufacturing capabilities alongside Regeneron's extensive biologics assets, which include bispecific antibodies from their proprietary VelocImmune® mice. The agreement targets the treatment of multiple solid tumors using Regeneron’s antibody portfolio. The companies share a commitment to precision oncology, planning to develop radio-diagnostics to assist in patient selection and treatment response.
Regarding the collaboration, John Lin, M.D., Ph.D., Senior Vice President of Oncology & Antibody Technology Research at Regeneron, emphasized the dynamic potential of targeted radiopharmaceuticals in oncology. Israel Lowy, M.D., Ph.D., Senior Vice President, Clinical Development Unit Head of Oncology at Regeneron, expressed excitement about the venture's potential to integrate these therapies with existing immunotherapy platforms to tackle challenging conditions such as lung cancer. Christian Behrenbruch, D.Phil., Managing Director and Group CEO of Telix, highlighted the complementary nature of the partnership and its promise in developing advanced therapeutics for difficult-to-treat cancers.
Financially, Telix receives an upfront payment of $40 million from Regeneron to access its manufacturing platform for four initial therapeutic programs. There is an option to expand with additional milestones and payments, potentially totaling $2.1 billion. The agreement operates under a 50/50 cost and profit-sharing model for global commercialization, although Telix can opt-out to earn substantial milestone payments and royalties instead.
Additionally, the companies will develop diagnostic assets jointly, with Telix taking the lead on commercialization and Regeneron earning a percentage of profits.
This collaboration highlights the ongoing evolution in cancer treatment modalities and the potential of integrating biologics with radiopharmaceutical approaches to address unmet needs in oncology.